Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials (Q44062340)

29 November 2017

0 references

0 references

Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials (English)

1 reference

29 November 2017

1 reference

1 reference

Eric J Bow

1

1 reference

29 November 2017

Michel Laverdière

2

1 reference

29 November 2017

Nathalie Lussier

3

1 reference

29 November 2017

Coleman Rotstein

4

1 reference

29 November 2017

Mary S Cheang

5

1 reference

29 November 2017

Stratis Ioannou

6

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 June 2002

1 reference

29 November 2017

1 reference

29 November 2017

94

1 reference

29 November 2017

3230-3246

1 reference

29 November 2017

12

1 reference

Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation

29 November 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Oral anticandidal prophylaxis in patients undergoing chemotherapy for acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Symposium on infectious complications of neoplastic disease (Part II). Chemoprophylaxis of fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Antifungal Prophylaxis during Neutropenia or Allogeneic Bone Marrow Transplantation: What is the State of the Art?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Infection in Acute Leukemia Patients Receiving Oral Nonabsorbable Antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Protective environment for marrow transplant recipients: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Prevention of gram-positive and Candida albicans infections using teicoplanin and fluconazole: a randomized study in neutropenic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients. The Canadian Fluconazole Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Meta-analysis in clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

An assessment of clinically useful measures of the consequences of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Clinical experience in prevention of candidiasis by nystatin in children with acute lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Fluconazole versus nystatin in the prevention of candida infections in children and adolescents undergoing remission induction or consolidation chemotherapy for cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Low-dose amphotericin B prophylaxis against invasive Aspergillus infections in allogeneic marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Increase inCandida kruseiInfection among Patients with Bone Marrow Transplantation and Neutropenia Treated Prophylactically with Fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Oral prophylaxis with miconazole or ketoconazole of invasive fungal disease in neutropenic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Effect of fluconazole prophylaxis on fever and use of amphotericin in neutropenic cancer patients. Bone Marrow Transplantation Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Prophylactic use of fluconazole in neutropenic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

A Double-Blind, Randomized, Placebo-Controlled Trial of Itraconazole Capsules as Antifungal Prophylaxis for Neutropenic Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Prevention of fungal sepsis in patients with prolonged neutropenia: a randomized, double-blind, placebo-controlled trial of intravenous miconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Comparative trial of ketoconazole and nystatin for prevention of fungal infection in neutropenic patients treated in a protective environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Invasive Aspergillosis in Acute Leukemia: Correlation with Nose Cultures and Antibiotic Use

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Multivariate analysis of factors associated with invasive fungal disease during remission induction therapy for acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Impact of air filtration on nosocomial Aspergillus infections. Unique risk of bone marrow transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Importance of Candida species other than C. albicans as pathogens in oncology patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlle

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

Infection risk and cancer chemotherapy: the impact of the chemotherapeutic regimen in patients with lymphoma and solid tissue malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

Protected environments and prophylactic antibiotics. A prospective controlled study of their utility in the therapy of acute leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

Infection prevention in acute nonlymphocytic leukemia. Laminar air flow room reverse isolation with oral, nonabsorbable antibiotic prophylaxis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

Nystatin prophylaxis in leukemia and lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

Candida infections in patients with acute leukemia: ineffectiveness of nystatin prophylaxis and relationship between oropharyngeal and systemic candidiasis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

The effect of fluconazole prophylaxis on fungal colonization in neutropenic cancer patients. Bone Marrow Transplantation Team

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

The effect of fluconazole as prophylaxis for neutropenic patients on the isolation of Candida spp. from surveillance cultures

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

The prophylactic use of low-dose amphotericin B in bone marrow transplant patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

Fluconazole in children: first experience with prophylaxis in chemotherapy-induced neutropenia in pediatric patients with cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

Orointestinal yeast colonization of paediatric oncologic patients during antifungal prophylaxis: results of quantitative culture and Candida serology and comparison of three polyenes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

[Comparison of oral fluconazole and amphotericin B prophylaxis against fungal infections in the neutropenic phase of patients treated with antileukemic agents]

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

Prophylaxis of oropharyngeal candidiasis with fluconazole.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies. Multicentre Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

Oral itraconazole plus nasal amphotericin B for prophylaxis of invasive aspergillosis in patients with hematological malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

Australian Dental Research Fund Trebitsch Scholarship. Efficacy of antifungal prophylaxis in bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

Itraconazole for prophylaxis of systemic mycoses in neutropenic patients with haematological malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

Prophylaxis of candidiasis in patients with leukemia and bone marrow transplants

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

Ketoconazole versus nystatin as prophylaxis against fungal infection for lymphoma patients receiving chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

Ketoconazole in the prevention of candidiasis in patients with cancer. A prospective, randomized, controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

Oral ketoconazole prophylaxis for Candida infections during induction therapy for acute leukaemia in adults: more bacteraemias

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

Fluconazole versus oral amphotericin B in preventing fungal infection in chemotherapy-induced neutropenic patients with haematological malignancies.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

Comparison of fluconazole with oral polyenes in the prevention of fungal infections in neutropenic patients. A prospective, randomized, single-center study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

Ketoconazole versus nystatin plus amphotericin B for fungal prophylaxis in severely immunocompromised patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

Oral ketoconazole and amphotericin B for the prevention of yeast colonization in patients with acute leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

Efficacy of Ketoconazole v Nystatin in Prevention of Fungal Infections in Neutropenic Patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

Predictors of adverse outcome in cancer patients with candidemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

Chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case-control study. Spanish Group of Allo-PBT

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10610

7 January 2021

Identifiers

DOI

10.1002/CNCR.10610

1 reference

29 November 2017

1 reference